A5012731168- Poxvirus research and outbreaks
- Bacillus and Francisella bacterial research
- Herpesvirus Infections and Treatments
- Yersinia bacterium, plague, ectoparasites research
- Viral Infections and Outbreaks Research
- Zoonotic diseases and public health
- Vector-borne infectious diseases
- Disaster Response and Management
- Virology and Viral Diseases
- Rabies epidemiology and control
- Ethics in Clinical Research
- Bacterial Identification and Susceptibility Testing
- Health Systems, Economic Evaluations, Quality of Life
- Healthcare cost, quality, practices
- Polyomavirus and related diseases
- Autism Spectrum Disorder Research
- Hepatitis B Virus Studies
- Pharmacological Effects of Natural Compounds
- Respiratory viral infections research
- SARS-CoV-2 and COVID-19 Research
- Delphi Technique in Research
- Malaria Research and Control
- Tuberculosis Research and Epidemiology
- Mosquito-borne diseases and control
- Viral Infections and Vectors
University of Oxford
2021-2025
Institut Pasteur de Bangui
2023
Institut Pasteur de Madagascar
2023
Background Due to limited diagnostic capacity and availability of point-of-care tests, diagnosis Clade I mpox in the geographical regions most affected is usually on clinical grounds. This may be complicated due similarity between varicella (chickenpox) lesions. Visual assessment lesions also used for determining progress assess patient outcomes trials. However, there has been no investigation into whether clinicians can (i) identify compared other viral (ii) differentiate lesion stages....
Abstract Background The new European Medicines Agency (EMA) Clinical Trials Information System (CTIS), based on the Regulation (CTR EU 536/2014), came into full effect 31 January 2022 and was intended to provide an easier, more streamlined approach registration of clinical trials taking place in Europe. Using experience gained regulatory framework from three multi-national research studies outbreak-prone infectious diseases, this article describes advantages shortcomings trial submission...
Abstract Background The global mpox outbreak which started in May 2022 was caused by a novel clade IIb variant of the virus (MPXV). It differed from traditional Western and Central Africa disease transmission patterns clinical presentation. Methods To address need for detailed virologic data, we conducted an observational cohort study (MOSAIC) during 2022-July 2023 individuals with confirmed MPXV infection enrolled six European Countries. Case-management decisions were left to attending...
The current recommendation for treating Lassa fever with ribavirin is supported only by weak evidence. Given the persistent effects in areas endemic transmission and epidemic potential, there an urgent need to reassess investigate other potential therapeutic candidates; however, a robust clinical trial method adapted epidemiology has not yet been established. We propose adaptive phase II/III multicenter randomized controlled platform that uses superiority framework equal allocation ratio...
ObjectivesThe ongoing global outbreak of mpox, caused by clade IIb mpox virus, poses significant challenges in accurately categorizing and assessing the diversity lesions. With lesion resolution being a key endpoint clinical trials observational studies, it is essential to evaluate inter-rater reliability agreement assessment among clinicians.MethodsClinicians experienced disease were surveyed online with 20 images. They categorized lesions into active, crusted, resolved, or unclassifiable...
Abstract Background There is currently no specific treatment recommended for monkeypox. This expanded access programme (EAP) aims to provide tecovirimat patients with monkeypox and collect data on patient treatment, disease evolution outcomes under a protocol contribute the evidence-base use of drug Methods Patients confirmed received according dosing. Data clinical signs symptoms were recorded daily during at follow-up visits. Blood or lesion samples taken day 28 assess viral presence by...
Abstract Background Due to limited diagnostic capacity and availability of point-of-care tests, diagnosis Clade I mpox in the regions most affected by disease is usually on clinical grounds may be complicated due similarity between varicella (chickenpox) lesions. Clinical assessment lesions also used for determining progress has been assess patient outcomes trials. However, there no investigation into whether clinicians can (i) identify compared other viral (ii) differentiate lesion stages....
Background Monkeypox is a viral zoonotic disease commonly reported in humans parts of Central and West Africa. This protocol for an Expanded Access Programme (EAP) to be implemented the African Republic, where Clade I monkeypox virus diseases primarily responsible most infections. The objective programme provide patients with confirmed access tecovirimat, novel antiviral targeting orthopoxviruses, collect data on clinical virological outcomes inform future research. Methods study will...
: This is a standardized, pre-positioned protocol for the coordinated evaluation of Lassa fever therapeutics. The product discussions that took place in 2021 and 2022 among international investigators from wide range scientific medical disciplines working together within West Africa Consortium (WALC).
Abstract During 2016–2022, PCR testing confirmed 100 mpox cases among 302 suspected in the Central African Republic. The highest detection rates were from active lesions (40%) and scabs (36%); cycle thresholds lower (≈18) than those for blood samples (≈33). Results consistent generic primer– clade I primer–specific tests.
Human mpox is a viral disease caused by an Orthopoxvirus, human virus (hMPXV), typically causing fever and rash. Mpox has historically been endemic to parts of Central West Africa, with small numbers imported cases reported elsewhere, but starting May 2022 unprecedented global outbreak clade IIb hMPXV was outside traditionally countries. This prompted the initiation MOSAIC, cohort study implemented in Europe Asia that aims describe clinical virologic outcomes PCR-confirmed disease, including...
Only one recommendation currently exists for the treatment of Lassa fever (LF), which is ribavirin administered in conjunction with supportive care. This primarily based on evidence generated from a single clinical trial that was conducted more than 30 years ago-the methodology and results have recently come under scrutiny. The requirement novel therapeutics reassessment therefore urgent. However, significant amount work now needs to be undertaken ensure future trials LF can consistently...
Abstract Background The new European Medicines Agency (EMA) Clinical Trials Information System (CTIS), based on the Regulation (CTR EU 536/2014), came into full effect 31 January 2022 and was intended to provide an easier, more streamlined approach registration of clinical trials taking place in Europe. Using experience gained regulatory framework from three multi-national research studies outbreak-prone infectious diseases, this article describes advantages shortcomings trial submission...
Background Among the many collaterals of COVID-19 pandemic is disruption health services and vital clinical research. has magnified challenges faced in research threatens to slow for urgently needed therapeutics Neglected Tropical Diseases (NTDs) diseases affecting most vulnerable populations. Here we explore impact on a trial plague strategies that have been considered ensure efforts continue. Methods To understand accrual rate, documented changes patterns all-cause consultations took place...
This article reports an update to the protocol of IMASOY trial, which was prospectively registered on clinicaltrials.gov (NCT04110340) in October 2019.
<ns4:p><ns4:bold>Background</ns4:bold>: This is a standardized, pre-positioned protocol for the coordinated evaluation of Lassa fever therapeutics. The product discussions that took place in 2021 and 2022 among international investigators from wide range scientific medical disciplines working together within West Africa Consortium (WALC).</ns4:p><ns4:p> <ns4:bold>Methods</ns4:bold>: clinical Phase II/III multicentre randomised controlled platform trial using superiority framework with an...
Abstract Introduction Conducting clinical research on treatments for emerging infectious diseases is often complicated by methodological challenges, such as the identification of appropriate outcome measures to assess treatment response and lack validated instruments available measure patient outcomes. In bubonic plague, some studies have assessed bubo size an indicator success, a widely assumed be indicative recovery. Evaluating this however challenging there no method measuring size. The...